White blood cells from cancer patients can be modified in the laboratory to react against tumours. However the poor trafficking of these cells to the tumour site and the fact that cancer cells can effectively turn off these gene-modified cells has hampered this approach. We propose to fully address these two critical issues using innovative techniques and mouse models that closely recapitulate the human setting. We anticipate that these studies will lead to a more effective therapy for patients.
A/Prof Phillip Darcy, A/Prof Michael Kershaw
Cancer Council Research Grant
Cancer Immunoloyg Research, Peter MacCallum Cancer Centre
Bruce Ward Grant-in-Aid
$100,000 per annum